Physician profile
Thomas Watkins
NPI 1861426348
$5,398.44
in general payments reported to CMS, 2019-2025
31 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $623 · 2021: $1,007 · 2022: $976 · 2023: $740 · 2024: $690 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,378 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,378.07 |
| Education | $183.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $930.51 | 2020-2025 | Spiriva Respimat, Stiolto Respimat, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $509.25 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $487.43 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $475.03 | 2019-2025 | |
| Novo Nordisk INC | $432.55 | 2019-2025 | Wegovy, Saxenda, Ozempic |
| Supernus Pharmaceuticals, INC. | $400.57 | 2020-2024 | Qelbree, Qelbree |
| Amgen INC. | $366.41 | 2021-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $264.81 | 2022-2025 | Qulipta |
| Astellas Pharma US INC | $205.79 | 2023-2025 | Veozah |
| Vanda Pharmaceuticals INC. | $204.78 | 2025 | Fanapt, Hetlioz |
| Glaxosmithkline, LLC. | $183.99 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $159.96 | 2020-2021 | |
| Mylan Specialty L.P. | $121.16 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $107.10 | 2020-2024 | Airsupra, Farxiga |
| Jazz Pharmaceuticals INC. | $70.03 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $56.21 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $54.52 | 2023-2025 | Sunosi, Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $48.47 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $47.00 | 2025 | Rexulti |
| Lundbeck LLC | $42.63 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.73 | 2025 | Xifaxan |
| Horizon Therapeutics Plc | $28.23 | 2021 | |
| Neurelis, INC. | $28.08 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $25.99 | 2022 | |
| Corcept Therapeutics | $20.25 | 2025 | Korlym |
| Almatica Pharma LLC | $19.10 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $17.98 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $17.74 | 2021 | |
| Paratek Pharmaceuticals, INC. | $14.57 | 2025 | Nuzyra |
| Seqirus USA INC | $13.56 | 2025 | Flucelvax, Fluad |
| Phathom Pharmaceuticals, INC. | $9.01 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Watkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.